Bench to Bedside: Current Perception Threshold Testing (CPT) to Measure Sensory Fiber Changes After Chemotherapy

2.50
Hdl Handle:
http://hdl.handle.net/10755/202198
Type:
Presentation
Title:
Bench to Bedside: Current Perception Threshold Testing (CPT) to Measure Sensory Fiber Changes After Chemotherapy
Abstract:
(41st Biennial Convention) Introduction: Chemotherapy induced peripheral neuropathy (CIPN) remains a significant complication of cancer treatment. For patients receiving taxanes and/or platinum chemotherapy, the incidence is as high as 84-100%. With no preventative or curative treatment, patients report symptoms ranging from constant numbness and tingling of the hands and/or feet to debilitating burning pain.  Symptoms often persist for several months or even years after the completion of treatment. As no “gold standard” measure exists, diagnosis depends upon the patient’s  report of symptoms, often when permanent neuronal injury has  occurred. When symptoms limit function, current  practice is to limit or discontinue treatment. A  need exists for a standard measure to accurately identify and predict CIPN, in an effort to limit long-term neuronal damage and improve prognosis. Purpose: The study purpose was to determine if CPT measurement accurately identifies CIPN and whether this measure predicts CIPN in patients receiving taxane and/or platinum regimens. Methods: This prospective study enrolled 35 chemotherapy naïve participants. Subjective and objective measurements, including CPT were collected during each chemotherapy treatment visit to assess sensory nerve function and the development of CIPN.   Results: At 2000 Hz, 250 Hz, and 5 Hz, the CPT identified 78%, 56%, and 33% of participants who developed CIPN, respectively. However, the false-positive rate was 70%, 50%, and 45%, respectively. Generalized linear mixed model analysis determined the only CPT frequency to predict the outcome of CIPN was at 250 Hz. A one unit increase in CPT at this frequency, increase the odds by 0.3% that a patient developed CIPN (OR=1.003, 95% CI=1.001-1.006, p=0.01).   Discussion: While this measure accurately identfied a majority of patients with CIPN at 2000 Hz, the false-postive rate was unnacceptibly high. No known studies to date have demonstrated the predictive capability of using CPT in this patient population. Further investigations are required to demonstrate repeatability of these results.       
Keywords:
Sensory nerve assessment; Chemotherapy-induced neuropathy; Current Perception Threshold
Repository Posting Date:
11-Jan-2012
Date of Publication:
4-Jan-2012
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleBench to Bedside: Current Perception Threshold Testing (CPT) to Measure Sensory Fiber Changes After Chemotherapyen_GB
dc.identifier.urihttp://hdl.handle.net/10755/202198-
dc.description.abstract(41st Biennial Convention) Introduction: Chemotherapy induced peripheral neuropathy (CIPN) remains a significant complication of cancer treatment. For patients receiving taxanes and/or platinum chemotherapy, the incidence is as high as 84-100%. With no preventative or curative treatment, patients report symptoms ranging from constant numbness and tingling of the hands and/or feet to debilitating burning pain.  Symptoms often persist for several months or even years after the completion of treatment. As no “gold standard” measure exists, diagnosis depends upon the patient’s  report of symptoms, often when permanent neuronal injury has  occurred. When symptoms limit function, current  practice is to limit or discontinue treatment. A  need exists for a standard measure to accurately identify and predict CIPN, in an effort to limit long-term neuronal damage and improve prognosis. Purpose: The study purpose was to determine if CPT measurement accurately identifies CIPN and whether this measure predicts CIPN in patients receiving taxane and/or platinum regimens. Methods: This prospective study enrolled 35 chemotherapy naïve participants. Subjective and objective measurements, including CPT were collected during each chemotherapy treatment visit to assess sensory nerve function and the development of CIPN.   Results: At 2000 Hz, 250 Hz, and 5 Hz, the CPT identified 78%, 56%, and 33% of participants who developed CIPN, respectively. However, the false-positive rate was 70%, 50%, and 45%, respectively. Generalized linear mixed model analysis determined the only CPT frequency to predict the outcome of CIPN was at 250 Hz. A one unit increase in CPT at this frequency, increase the odds by 0.3% that a patient developed CIPN (OR=1.003, 95% CI=1.001-1.006, p=0.01).   Discussion: While this measure accurately identfied a majority of patients with CIPN at 2000 Hz, the false-postive rate was unnacceptibly high. No known studies to date have demonstrated the predictive capability of using CPT in this patient population. Further investigations are required to demonstrate repeatability of these results.       en_GB
dc.subjectSensory nerve assessmenten_GB
dc.subjectChemotherapy-induced neuropathyen_GB
dc.subjectCurrent Perception Thresholden_GB
dc.date.available2012-01-11T11:15:18Z-
dc.date.issued2012-01-04en_GB
dc.date.accessioned2012-01-11T11:15:18Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.